46,122 Shares in Zoetis Inc. $ZTS Purchased by Munich Reinsurance Co Stock Corp in Munich

Munich Reinsurance Co Stock Corp in Munich acquired a new stake in shares of Zoetis Inc. (NYSE:ZTS) in the third quarter, HoldingsChannel reports. The fund acquired 46,122 shares of the company’s stock, valued at approximately $6,749,000.

Other institutional investors also recently made changes to their positions in the company. Halbert Hargrove Global Advisors LLC increased its stake in shares of Zoetis by 496.6% in the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock worth $25,000 after buying an additional 144 shares during the last quarter. Financial Consulate Inc. bought a new stake in shares of Zoetis in the 3rd quarter worth about $39,000. SJS Investment Consulting Inc. raised its stake in shares of Zoetis by 1,606.3% in the 3rd quarter. SJS Investment Consulting Inc. now owns 273 shares of the company’s stock valued at $40,000 after purchasing an additional 257 shares in the last quarter. TruNorth Capital Management LLC bought a new position in shares of Zoetis during the third quarter worth about $42,000. Finally, Financial Gravity Companies Inc. acquired a new position in Zoetis in the second quarter worth about $47,000. 92.80% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have issued reports on ZTS shares. Morgan Stanley set a $160.00 price objective on Zoetis in a research note on Thursday, December 18th. HSBC set a $140.00 price target on Zoetis in a research report on Wednesday, December 10th. William Blair reiterated an “outperform” rating on shares of Zoetis in a research note on Monday, March 2nd. Bank of America raised their price target on shares of Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a research report on Friday, February 13th. Finally, Stifel Nicolaus lowered their price objective on shares of Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a research report on Tuesday, November 18th. Six research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $152.91.

Zoetis Trading Down 0.6%

Shares of NYSE:ZTS opened at $121.54 on Friday. The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71. The company’s 50-day moving average price is $126.06 and its 200 day moving average price is $133.05. The company has a market cap of $51.31 billion, a PE ratio of 20.19, a P/E/G ratio of 1.85 and a beta of 0.95. Zoetis Inc. has a fifty-two week low of $115.25 and a fifty-two week high of $177.00.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.40 by $0.08. The company had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. Zoetis’s revenue was up 3.0% compared to the same quarter last year. During the same quarter last year, the business earned $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Sell-side analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be paid a $0.53 dividend. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 annualized dividend and a dividend yield of 1.7%. Zoetis’s dividend payout ratio is presently 35.22%.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.